Seribantumab

Seribantumab (INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2]

Seribantumab
Monoclonal antibody
Type?
SourceHuman
TargetHER3
Clinical data
Other namesMM-121
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6340H9810N1690O1986S52
Molar mass143151.18 g·mol−1

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.